Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.59 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735078 | 1.00 | LMNA (0.61) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL590358 | 1.00 | LMNA (0.61) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL4618949 | 0.92 | HTT (0.63) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL22171710 | 0.90 | HTT (0.62) | LMNASMN1; SMN2HTTTGM2KEAP1 | |
| SCHEMBL3701581 | 0.90 | LMNA (0.60) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL18667866 | 0.87 | LMNA (0.60) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL7775648 | 0.87 | HTT (0.61) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL7775652 | 0.87 | HTT (0.61) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL18667208 | 0.87 | LMNA (0.60) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL7752769 | 0.86 | LMNA (0.67) | LMNASMN1; SMN2SLC1A3SLC1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134695-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-05-17 | — | — | US | disclosed |
| US-9896444-B2 | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-20160200705-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2016-07-14 | — | — | US | disclosed |
| US-9340537-B2 | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVATIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| US-20150126485-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| CN-104302634-A | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG | 2015-01-21 | — | — | CN | disclosed |
| US-8138175-B2 | Heterocyclyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-2321285-A1 | DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. Hoffmann-La Roche AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010012619-A1 | DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | WO | disclosed |
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR5 | LMNA 3760/4885SMN1; SMN2 4455/4885SLC1A3 1680/4885 |
| US-20160200705-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | LMNA 4457/4885SMN1; SMN2 3874/4885SLC1A3 3433/4885 |
| US-20150126485-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | LMNA 4722/4885SMN1; SMN2 3946/4885SLC1A3 3256/4885 |
| US-20180134695-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | LMNA 4592/4885SMN1; SMN2 3863/4885SLC1A3 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.